Clinical Trial Update: A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction [Phase 1]

View source ↗

Summary

Phase 1 study of Brivanib (BMS-582664) in hepatocellular carcinoma patients with mild to severe liver dysfunction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Brivanib (brivanib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Carcinoma, Hepatocellular | Phase 1 | Status: COMPLETED